Abstract:Background & Aims: PARP1 is a key mediator of cellular stress responses and critical in multiple physiological and pathophysiological processes of cells. However, whether it is involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) remains elusive.Methods: We analysed PARP1 activity in the liver of mice on a high fat diet (HFD), and samples from NAFLD patients. Gain- or loss-of-function approaches were used to investigate the roles and mechanisms of hepatic PARP1 in the pathogenesis of NAFLD.Results: PARP1 is activated in fatty liver of HFD-fed mice. Pharmacological or genetic manipulations of PARP1 are sufficient to alter the HFD-induced hepatic steatosis and inflammation. Mechanistically we identified peroxisome proliferator-activated receptor alpha (PPAR alpha) as a substrate of PARP1-mediated poly (ADP-ribosyl) ation. This poly(ADP-ribosyl) ation of PPAR alpha inhibits its recruitment to target gene promoters and its interaction with SIRT1, a key regulator of PPAR alpha signaling, resulting in suppression of fatty acid oxidation upregulation induced by fatty acids. Moreover, we show that PARP1 is a transcriptional repressor of PPAR alpha gene in human hepatocytes, and its activation suppresses the ligand (fenofibrate)-induced PPARa transactivation and target gene expression. Importantly we demonstrate that liver biopsies of NAFLD patients display robust increases in PARP activity and PPAR alpha poly(ADP-ribosyl) ation levels.Conclusions: Our data indicate that PARP1 is activated in fatty liver, which prevents maximal activation of fatty acid oxidation by suppressing PPAR alpha signaling. Pharmacological inhibition of PARP1 may alleviate PPARa suppression and therefore have therapeutic potential for NAFLD.Lay summary: PARP1 is activated in the non-alcoholic fatty liver of mice and patients. Inhibition of PARP1 activation alleviates lipid accumulation and inflammation in fatty liver of mice. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease

Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease

PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets

Peroxisome Proliferator-Activated Receptors and Non-Alcoholic Fatty Liver Diseases

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Advances between PPARα and non-alcoholic fatty liver disease

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

The Roles and Interaction of FXR and PPARs in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Roles of Peroxisome Proliferator-Activated Receptor in the Pathogenesis of Ethanol-Induced Liver Disease

A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma

PPARs as Nuclear Receptors for Nutrient and Energy Metabolism

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

PPARs: Modulating Lipotoxicity and Thus Inhibiting Fibrosis

Parp1-Mediated Ppar Alpha Poly(Adp-Ribosyl)Ation Suppresses Fatty Acid Oxidation In Non-Alcoholic Fatty Liver Disease

The Roles of PPARs in Human Diseases

Crosstalk Between PPARs and Gut Microbiota in NAFLD.

Targeting PPARα for the Treatment and Understanding of Cardiovascular Diseases.